Purdue Pharma is about to stop existing. By Friday of this week, according to reporting from the Associated Press, the OxyContin maker will be dissolved and replaced by a new entity called Knoa Pharma, a company ostensibly designed to combat the very crisis it once fueled. On the surface, this sounds like accountability. A federal judge delivered the company’s criminal sentence this week, the final legal piece needed to make a sprawling settlement official. The guilty plea. The $8.3 billion in forfeitures, fines, and penalties. The Sackler family’s pledge to contribute up to $7 billion over 15 years.
But step closer and the satisfaction cracks.
When a Settlement Isn’t Justice
U.S. District Judge Madeline Cox Arleo heard from victims for about five hours before signing off on the deal. Mothers who lost sons to overdose. A teenager born into withdrawal whose mother later died. People prescribed OxyContin after accidents who spent years battling addiction and financial ruin. Many begged her to reject the negotiated sentence. Alexis Pluis, a mother from upstate New York whose son died of opioids in 2014, couldn’t even prove he’d been prescribed OxyContin because she couldn’t locate 23-year-old medical records. “We still deserve justice,” she told the judge. “And this isn’t it.”
Judge Arleo appeared moved. At times she seemed on the verge of tears. She said she would keep photos of the victims’ lost loved ones in her chambers for as long as she serves on the bench. She had sharp words for federal regulators who approved OxyContin without catching warning signs of abuse. She noted the bitter irony: she has sentenced street-level drug dealers to prison for selling OxyContin, yet those who engineered the epidemic will face no jail time.
“It is not lost on me that those who started the epidemic will not serve a sentence,” Arleo said.
The Math Doesn’t Add Up
Here’s where the cynicism deepens. The federal government negotiated to collect just $225 million in criminal fines, even though Purdue admitted in court to running what the judge called “a purposeful, intentional and sophisticated crime scheme.” According to the AP’s reporting, the company told the DEA it had an effective program to prevent its powerful painkillers from reaching the black market, when in fact it did not. It paid doctors through a speakers program to prescribe the drugs. It paid an electronic medical records company to send doctors patient information designed to encourage more opioid prescriptions.
These weren’t mistakes. They were calculated moves.
Payments to individual victims are expected to range from about $8,000 to $16,000. For people whose loved ones died, whose families fractured, whose lives derailed, that figure sits somewhere between symbolic and insulting. Some victims won’t even qualify for payments because they can’t produce decades-old prescriptions.
The broader settlement, spread across states, local governments, and tribal nations, is being described as one of the largest in the history of pharmaceutical litigation. Yet most of that money is earmarked for government entities to use fighting the opioid crisis, not for the people who actually suffered it.
The Sackler Shield
Then there’s the matter of the Sackler family, who own Purdue. They’re pledging to pay up to $7 billion over 15 years, not upfront. Judge Arleo didn’t hide her skepticism. “They’d rather pay it from future money than pay it now,” she said.
The family will also receive significant legal protection as part of the deal. Members of the Sackler family will be shielded from future opioid lawsuits from those who accept settlement payments. That’s leverage, essentially monetized. They’ve agreed not to object if their names come off museums and other institutions they’ve funded, a gesture that feels more like damage control than consequence.
From 2008 through 2018, the Sacklers received about $10.7 billion in payments from Purdue. They claim nearly half went to taxes on behalf of the business. Do the math yourself on whether 15-year payment plans feel proportional to a generation of addiction and death.
What Actually Changes
The settlement isn’t entirely hollow. Millions of internal Purdue documents will be made public. The new company, Knoa Pharma, will have a board appointed by the states and an explicit mission to fight the opioid crisis. That transparency and structural change matter, even if they feel insufficient.
And the overall settlement landscape is genuinely massive. Across all pharmaceutical, wholesaler, and pharmacy settlements in recent years, the total exceeds $50 billion. Most of that money is supposed to address the overdose epidemic. The question is whether government entities will actually deploy it effectively, or whether it becomes another line item in budgets that never quite reach those who need it most.
The Reckoning We Didn’t Get
What’s striking about this settlement is what it reveals about how American business and law actually work. A company engineered one of the deadliest epidemics in modern history, and in response, the company ceases to exist while its architects remain free. No individual executives faced criminal charges. No one is going to prison. The settlement is being called historic, but only because we’ve normalized the idea that corporate crimes can be addressed primarily through financial transfers rather than personal accountability.
Over 900,000 Americans have died from opioids since 1999, according to federal data cited in the AP reporting. Judge Arleo’s words hung in the courtroom like an unresolved chord: “It is not lost on me that those who started the epidemic will not serve a sentence.”
The question lingering after all the legal machinery grinds to a halt this week is whether any amount of money can actually settle a crime this vast, or whether some debts simply can’t be paid.
